Guggenheim analyst Eddie Hickman initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research initiated with an Outperform at RBC Capital
- GH Research PLC Reports 2024 Financial Results and Clinical Progress
- GH Research’s Promising Growth Potential: Buy Rating Backed by Strong Clinical Data and Financial Position
- Optimistic Buy Rating for GH Research Driven by Promising Clinical Data and Strong Financial Outlook
- Promising Trial Results and Strong Financials Justify Buy Rating for GH Research
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue